Osteoarthritis Trial, Recruiting NCT06388811 Sponsor: Istanbul University Condition: Osteoarthritis
Back to Osteoarthritis

Osteoarthritis Trial, Recruiting

NCT06388811
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Patient group (people with early knee symptoms):

  • People who meet specific diagnostic criteria for early-stage knee osteoarthritis, based on a combination of symptoms (such as pain when going up and down stairs or pain that gets worse with activity) and risk factors (confirm with trial site for full details)
  • People aged 40 or older
  • People who are able to read and write in Turkish
  • People who are able to attend all required follow-up visits
  • People who have signed the informed consent form

Control group (people without knee problems):

  • People who have no knee pain
  • People aged 40 or older
  • People who are able to read and write in Turkish
  • People who are able to attend all required follow-up visits
  • People who have signed the informed consent form

Who may not be able to join:

Patient group:

  • People who have an active inflammatory joint condition (such as rheumatoid arthritis)
  • People who experience widespread pain throughout their body
  • People under the age of 40
  • People who already have a confirmed diagnosis of knee osteoarthritis at stages 1–4 on the Kellgren and Lawrence scale (a standard medical grading system)
  • People who have had a recent knee injury or trauma
  • People whose knee symptoms have been present for more than 6 months
  • People who have difficulty understanding or completing questionnaires due to cognitive or mental capacity reasons

Control group:

  • People who have any knee pain
  • People under the age of 40
  • People who have difficulty understanding or completing questionnaires due to cognitive or mental capacity reasons

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +905333558843

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Istanbul University
Registry
ClinicalTrials.gov
Start date
19 February 2025
Est. completion
19 March 2025

Where this trial is recruiting

Turkey (Türkiye)

Primary endpoints

Numeric Rating Scale; Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov